Get the Stockscreener App
7.68
10.39%
-0.89
After Hours:
7.67
-0.010
-0.13%
Conexeu Sciences Inc stock is traded at $7.68, with a volume of 140.63K.
It is down -10.39% in the last 24 hours and down -29.93% over the past month.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
See More
Previous Close:
$8.57
Open:
$8.6
24h Volume:
140.63K
Relative Volume:
2.06
Market Cap:
$205.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.51%
1M Performance:
-29.93%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.30
$8.725
1-Week Range:
$7.30
$10.19
52-Week Range:
$7.30
$18.79
Conexeu Sciences Inc Stock (CNXU) Company Profile
Name
Conexeu Sciences Inc
Sector
Industry
Phone
604-315-4722
Address
50 WEST LIBERTY STREET, SUITE 880, RENO
Compare CNXU vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNXU
Conexeu Sciences Inc
|
7.68 | 229.32M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Conexeu Sciences Inc Stock (CNXU) Latest News
Top Conexeu Sciences (CNXU) Competitors 2026 - MarketBeat
Short Interest in Conexeu Sciences Inc. (NASDAQ:CNXU) Expands By 357.1% - MarketBeat
CNXU|Conexeu Sciences Ord Shs|Price:8.570|Chg%:-0.580 - TradingKey
Conexeu Sciences Ord Shs (CNXU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Conexeu Sciences Inc. Revenue Breakdown – NASDAQ:CNXU - TradingView
Paisley Capital reports 1.8M-share position in Conexeu Sciences Inc. (CNXU) - Stock Titan
David Robert Bogart Net Worth (2026) - GuruFocus
Conexeu Sciences (CNXU) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ana Lucia Bastiani Posner Net Worth (2026) - GuruFocus
Aaron Solomon Farberg Net Worth (2026) - GuruFocus
Jeffrey Nathan Sharpe Net Worth (2026) - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Conexeu Sciences Inc.Common Stock (CNXU) Stock Price, News, Quote & History - FinancialContent
Breakeven Is Near for Pulsar Group plc (LON:PULS) - simplywall.st
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
GLP-1 Aesthetic Care Projected to Reach $2B by 2030 - Stock Titan
CNXU Price Today: Conexeu Sciences Inc. Stock Price, Quote & Chart | MEXC - mexc.co
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. - PR Newswire
A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next - marketscreener.com
Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off - simplywall.st
Conexeu Sciences Launches CXU™ Platform for Injectable Aesthetics - Intellectia AI
Stocks & Markets Podcast: Regenerative Medicine’s Next Leap with Conexeu Sciences CEO - TheStreet Pro
Conexeu targets $2B injectable aesthetics marke... - Pluang
Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform - marketscreener.com
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It - The Manila Times
OneWater Marine Inc. (NASDAQ:ONEW): Is Breakeven Near? - simplywall.st
CNXU Stock Price and Chart — NASDAQ:CNXU - TradingView
Claudia Itze Chavez Munoz Net Worth (2026) - GuruFocus
Michael G. Wright Net Worth (2026) - GuruFocus
April Lynn Burke Net Worth (2026) - GuruFocus
Stephen Douglas Inouye Net Worth (2026) - GuruFocus
Conexeu Sciences (CNXU) Insider Trading Activity 2026 - MarketBeat
Flourish Adoption - AOL.com
CNXU Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Onepointtwo Capital Ventures Llc Net Worth (2026) - GuruFocus
Miles David Harrison Net Worth (2026) - GuruFocus
Onepointtwo Capital Ventures Ii Llc Net Worth (2026) - GuruFocus
Brian Keith Pilcher Net Worth (2026) - GuruFocus
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics - Investing News Network
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Conexeu Sciences (CNXU) Targets Medical Aesthetics Market Amid G - GuruFocus
Conex Completes 12-Month P.R.O.O.F Preclinical Study, Targets Q1 2027 510(k) for Wound Care - TradingView
[8-K] Conexeu Sciences Inc. Reports Material Event - Stock Titan
Sanken Electric Co., Ltd. (6707) - MSN
A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It - PR Newswire
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill - The Manila Times
Enterprise value to EBITDA forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Conexeu Sciences (CNXU) Earnings Date and Reports 2026 - MarketBeat
CNXU Should I Buy - Intellectia AI
Conexeu Sciences Inc. Common Stock (NASDAQ: CNXU) Stock Price, News & Analysis - Kalkine
Price to book forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Conexeu Sciences Inc Stock (CNXU) Financials Data
There is no financial data for Conexeu Sciences Inc (CNXU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):